NewLink (NASDAQ:NLNK) and Lumos Pharma sign
a definitive merger agreement that will result in Lumos becoming a
wholly-owned subsidiary and NewLink taking on the Lumos name and new
“LUMO” ticker.
Lumos shareholders will receive NLNK common stock
shares in an exchange that will leave Lumos holders with a 50% stake in
the resulting entity.
This merger is expected to provide the financial
support necessary to expedite the clinical development of LUM-201 for
PGHD, which could start its Phase 2b clinical trial in mid-2020.
The deal is expected to close in Q1 2020.
NLNK shares are down 1.3% after hours to $1.57.
https://seekingalpha.com/news/3502736-newlink-minus-1_3-percent-lumos-merger
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.